MYNZ
Mainz Biomed
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
MYNZ Profile
Mainz Biomed N.V.
A molecular genetics diagnostic company specializing in the early detection of cancer
Robert Koch Strasse 50, 55129 Mainz, Germany
--
Mainz Biomed N.V. was incorporated in the Netherlands on March 8, 2021. The company is a molecular genetics cancer diagnostic company established in 2021 to acquire PharmGenomics GmbH with the aim of commercializing its product portfolio in Europe and the United States. The company focuses on the diagnostic side of the cancer industry. The company competes with other entities that develop and offer diagnostic tests to detect the presence of cancer. The company's core product is the CRC screening stool DNA test, and they are in the early stages of researching a similar test for pancreatic cancer.